title: Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy.
abstract: Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.
authors.forename: H
authors.initials: H
authors.lastname: Azuma
authors.forename: M
authors.initials: M
authors.lastname: Oshima
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: A
authors.initials: A
authors.lastname: Okuno
authors.forename: I
authors.initials: I
authors.lastname: Kawabata
authors.forename: K
authors.initials: K
authors.lastname: Banba
authors.forename: H
authors.initials: H
authors.lastname: Murahashi
authors.forename: T
authors.initials: T
authors.lastname: Sekine
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Ikebuchi
authors.forename: H
authors.initials: H
authors.lastname: Ikeda
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014923:Wiskott-Aldrich Syndrome / Q000097:blood / Q000276:immunology* / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2; D011994:Recombinant Proteins